Axxam, Polyphor Team on Drug Screening | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Italian drug screening technologies company Axxam will collaborate with Swiss firm Polyphor on ion channel-based research, the firms said today.

The partners will use their respective drug discovery and screening platforms to identify drug candidates for therapeutic areas including pain, inflammation, and metabolic disorders.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.